Phreesia Reports Q1 Fiscal 2027 Earnings Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 47 minutes ago
0mins
Source: seekingalpha
- Revenue Growth: Phreesia reported Q1 revenue of $130.9 million, a 13% year-over-year increase, with Payment Solutions leading at 40% growth, indicating strong performance in the healthcare payment sector and potential for increased market share.
- New Financing Arrangement: The company successfully completed a $275 million senior secured revolving credit facility, using $92 million to repay its bridge loan, enhancing financial flexibility and providing capital for future expansion and investments.
- Client Growth: The average number of healthcare services clients reached 4,708 in Q1, an increase of 50 from the prior quarter and a 7% year-over-year growth, demonstrating effective strategies in client acquisition and retention.
- Improved Profitability: Adjusted EBITDA was $30.5 million, significantly up from $20.8 million in the prior year, with an EBITDA margin of 23%, reflecting ongoing improvements in cost control and operational efficiency.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHR
Wall Street analysts forecast PHR stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.950
Low
24.00
Averages
29.09
High
35.00
Current: 8.950
Low
24.00
Averages
29.09
High
35.00
About PHR
Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Phreesia Reports Q1 Fiscal 2027 Earnings Highlights
- Revenue Growth: Phreesia reported Q1 revenue of $130.9 million, a 13% year-over-year increase, with Payment Solutions leading at 40% growth, indicating strong performance in the healthcare payment sector and potential for increased market share.
- New Financing Arrangement: The company successfully completed a $275 million senior secured revolving credit facility, using $92 million to repay its bridge loan, enhancing financial flexibility and providing capital for future expansion and investments.
- Client Growth: The average number of healthcare services clients reached 4,708 in Q1, an increase of 50 from the prior quarter and a 7% year-over-year growth, demonstrating effective strategies in client acquisition and retention.
- Improved Profitability: Adjusted EBITDA was $30.5 million, significantly up from $20.8 million in the prior year, with an EBITDA margin of 23%, reflecting ongoing improvements in cost control and operational efficiency.
See More
Phreesia Faces Class Action Lawsuit Risks
- Lawsuit Background: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased Phreesia (NYSE: PHR) stock between May 8, 2025, and March 30, 2026, alleging the company misled investors about the sustainability of growth in its Network Solutions business, which could impact future revenues.
- Revenue Outlook Downgrade: On March 30, 2026, Phreesia announced a reduction in its fiscal 2027 revenue outlook from $545 million-$559 million to $510 million-$520 million, indicating reduced visibility into future spending commitments, resulting in a stock price drop of approximately 27% the following day.
- Decreased Client Spending: The complaint highlights that Phreesia's Network Solutions clients are committing lower spending levels for the second half of fiscal 2027 than anticipated, and pharmaceutical companies are reducing marketing expenditures due to regulatory impacts, increasing variability in revenue forecasting.
- Shareholder Action Recommendations: Shareholders are advised to submit their papers by July 13, 2026, to serve as lead plaintiffs in the class action, representing other shareholders in the litigation, while those who choose not to participate can remain absent class members and retain their rights to recovery.
See More
Phreesia Q4 Revenue Surges 19.3% to $130.9M, Beating Expectations
- Significant Revenue Growth: Phreesia reported Q4 2026 revenue of $130.9 million, reflecting a 19.3% year-over-year increase, surpassing market expectations by $0.83 million, indicating robust performance in the healthcare services sector.
- Expanded Client Base: The average number of healthcare services clients reached 4,708, up 7% year-over-year, demonstrating the company's success in client acquisition and market penetration.
- Improved Profitability: The net income for the quarter was $3.0 million, a turnaround from a net loss of $3.9 million in the same period last year, showcasing a significant improvement in the company's profitability and operational efficiency.
- Strong Cash Flow: Net cash provided by operating activities was $23.9 million, a 60.4% increase from $14.9 million in the prior year, providing strong financial support for ongoing investments and expansion efforts.
See More
Phreesia Faces Shareholder Class Action Lawsuit
- Lawsuit Background: Phreesia, Inc. (NYSE: PHR) is facing a shareholder class action lawsuit alleging that the company made false and misleading statements while failing to disclose risks associated with slowing growth in its Network Solutions segment, which could significantly impact investor decisions.
- Investor Losses: Shareholders who purchased Phreesia stock between May 8, 2025, and March 30, 2026, and experienced losses are encouraged to contact Holzer & Holzer law firm to discuss their legal rights, indicating that the lawsuit may affect a wide range of investors' interests.
- Legal Representation: Holzer & Holzer, a top-rated securities litigation law firm, focuses on vigorously representing shareholders and investors in litigation nationwide, having recovered hundreds of millions of dollars for victims of fraud and corporate misconduct, showcasing their expertise in securities litigation.
- Lawsuit Deadline: Investors must apply to be appointed lead plaintiff in the case by July 13, 2026, emphasizing the importance of timely legal action to protect their rights and participate in potential compensation proceedings.
See More
Phreesia Faces Federal Securities Class Action
- Lawsuit Deadline: Phreesia, Inc. reminds investors that July 13, 2026, is the deadline to apply for lead plaintiff status in a federal securities class action, emphasizing the importance of timely action for investor rights protection.
- False Statements Allegation: The lawsuit alleges that Phreesia made materially false and misleading statements from May 8, 2025, to March 30, 2026, concealing the slowing demand and reduced visibility in its Network Solutions segment, potentially leading to investor losses.
- Revenue Guidance Cut: On March 30, 2026, Phreesia announced a significant reduction in revenue growth projections for fiscal year 2027, attributing this shortfall to macroeconomic factors and weakened pharmaceutical marketing commitments, highlighting the company's vulnerabilities in the market.
- Stock Price Volatility: Following the revenue guidance cut, Phreesia's stock price plummeted from $11.41 to $8.38 per share, a decline of approximately 27%, reflecting market concerns and a loss of confidence in the company's future performance.
See More
Phreesia Set to Announce Q1 Earnings on May 27
- Earnings Announcement: Phreesia (PHR) is set to release its Q1 earnings on May 27 after market close, with consensus EPS estimates at $0.29, reflecting a remarkable 514.3% year-over-year increase, indicating significant improvement in profitability.
- Revenue Expectations: The anticipated revenue for Q1 is $130.07 million, representing a 12.2% year-over-year growth, although the company faces challenges from network solutions and the integration of AccessOne, suggesting potential growth despite headwinds.
- Historical Performance Review: Over the past year, Phreesia has not missed EPS estimates, achieving a 100% beat on revenue estimates, which highlights strong revenue management, although profitability still requires improvement.
- Revision Trends: In the last three months, there have been no upward revisions for EPS estimates, with 6 downward adjustments, while revenue estimates also saw no upward revisions and 15 downward adjustments, reflecting a lack of confidence in the company's future performance.
See More
Phreesia Reports Q1 Fiscal 2027 Earnings Highlights
- Revenue Growth: Phreesia reported Q1 revenue of $130.9 million, a 13% year-over-year increase, with Payment Solutions leading at 40% growth, indicating strong performance in the healthcare payment sector and potential for increased market share.
- New Financing Arrangement: The company successfully completed a $275 million senior secured revolving credit facility, using $92 million to repay its bridge loan, enhancing financial flexibility and providing capital for future expansion and investments.
- Client Growth: The average number of healthcare services clients reached 4,708 in Q1, an increase of 50 from the prior quarter and a 7% year-over-year growth, demonstrating effective strategies in client acquisition and retention.
- Improved Profitability: Adjusted EBITDA was $30.5 million, significantly up from $20.8 million in the prior year, with an EBITDA margin of 23%, reflecting ongoing improvements in cost control and operational efficiency.
See More
Phreesia Faces Class Action Lawsuit Risks
- Lawsuit Background: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased Phreesia (NYSE: PHR) stock between May 8, 2025, and March 30, 2026, alleging the company misled investors about the sustainability of growth in its Network Solutions business, which could impact future revenues.
- Revenue Outlook Downgrade: On March 30, 2026, Phreesia announced a reduction in its fiscal 2027 revenue outlook from $545 million-$559 million to $510 million-$520 million, indicating reduced visibility into future spending commitments, resulting in a stock price drop of approximately 27% the following day.
- Decreased Client Spending: The complaint highlights that Phreesia's Network Solutions clients are committing lower spending levels for the second half of fiscal 2027 than anticipated, and pharmaceutical companies are reducing marketing expenditures due to regulatory impacts, increasing variability in revenue forecasting.
- Shareholder Action Recommendations: Shareholders are advised to submit their papers by July 13, 2026, to serve as lead plaintiffs in the class action, representing other shareholders in the litigation, while those who choose not to participate can remain absent class members and retain their rights to recovery.
See More
Phreesia Q4 Revenue Surges 19.3% to $130.9M, Beating Expectations
- Significant Revenue Growth: Phreesia reported Q4 2026 revenue of $130.9 million, reflecting a 19.3% year-over-year increase, surpassing market expectations by $0.83 million, indicating robust performance in the healthcare services sector.
- Expanded Client Base: The average number of healthcare services clients reached 4,708, up 7% year-over-year, demonstrating the company's success in client acquisition and market penetration.
- Improved Profitability: The net income for the quarter was $3.0 million, a turnaround from a net loss of $3.9 million in the same period last year, showcasing a significant improvement in the company's profitability and operational efficiency.
- Strong Cash Flow: Net cash provided by operating activities was $23.9 million, a 60.4% increase from $14.9 million in the prior year, providing strong financial support for ongoing investments and expansion efforts.
See More
Phreesia Faces Shareholder Class Action Lawsuit
- Lawsuit Background: Phreesia, Inc. (NYSE: PHR) is facing a shareholder class action lawsuit alleging that the company made false and misleading statements while failing to disclose risks associated with slowing growth in its Network Solutions segment, which could significantly impact investor decisions.
- Investor Losses: Shareholders who purchased Phreesia stock between May 8, 2025, and March 30, 2026, and experienced losses are encouraged to contact Holzer & Holzer law firm to discuss their legal rights, indicating that the lawsuit may affect a wide range of investors' interests.
- Legal Representation: Holzer & Holzer, a top-rated securities litigation law firm, focuses on vigorously representing shareholders and investors in litigation nationwide, having recovered hundreds of millions of dollars for victims of fraud and corporate misconduct, showcasing their expertise in securities litigation.
- Lawsuit Deadline: Investors must apply to be appointed lead plaintiff in the case by July 13, 2026, emphasizing the importance of timely legal action to protect their rights and participate in potential compensation proceedings.
See More
Phreesia Faces Federal Securities Class Action
- Lawsuit Deadline: Phreesia, Inc. reminds investors that July 13, 2026, is the deadline to apply for lead plaintiff status in a federal securities class action, emphasizing the importance of timely action for investor rights protection.
- False Statements Allegation: The lawsuit alleges that Phreesia made materially false and misleading statements from May 8, 2025, to March 30, 2026, concealing the slowing demand and reduced visibility in its Network Solutions segment, potentially leading to investor losses.
- Revenue Guidance Cut: On March 30, 2026, Phreesia announced a significant reduction in revenue growth projections for fiscal year 2027, attributing this shortfall to macroeconomic factors and weakened pharmaceutical marketing commitments, highlighting the company's vulnerabilities in the market.
- Stock Price Volatility: Following the revenue guidance cut, Phreesia's stock price plummeted from $11.41 to $8.38 per share, a decline of approximately 27%, reflecting market concerns and a loss of confidence in the company's future performance.
See More
Phreesia Set to Announce Q1 Earnings on May 27
- Earnings Announcement: Phreesia (PHR) is set to release its Q1 earnings on May 27 after market close, with consensus EPS estimates at $0.29, reflecting a remarkable 514.3% year-over-year increase, indicating significant improvement in profitability.
- Revenue Expectations: The anticipated revenue for Q1 is $130.07 million, representing a 12.2% year-over-year growth, although the company faces challenges from network solutions and the integration of AccessOne, suggesting potential growth despite headwinds.
- Historical Performance Review: Over the past year, Phreesia has not missed EPS estimates, achieving a 100% beat on revenue estimates, which highlights strong revenue management, although profitability still requires improvement.
- Revision Trends: In the last three months, there have been no upward revisions for EPS estimates, with 6 downward adjustments, while revenue estimates also saw no upward revisions and 15 downward adjustments, reflecting a lack of confidence in the company's future performance.
See More
